First Round of Abstract Submission Ends: Apr 25, 2024
Extended Early Bird Ends: Apr 20, 2024

Keynote Speakers

Prof. Campbell McInnes
University of South Carolina, USA
Title: Will update soon
I obtained my Ph.D. in 1991 (New methodology for Solid Phase Peptide Synthesis) and afterwards carried out post-doctoral research at the University of Alberta in Canada on peptide-receptor interactions by multidimensional NMR. I then worked for Cyclacel in Dundee, UK from 1999-2006 on many cancer related drug discovery projects. I joined the University of South Carolina in 2006 and achieved the rank of Full Professor in 2017. My primary research focus is on developing non-ATP competitive inhibitors for protein kinases that are deregulated in cancer through targeting their protein - protein interactions.
Prof. Shiguo Sun
Northwest A&F University, China
Title: Will update soon
Shiguo Sun is a professor and doctoral supervisor at the Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, obtained his Ph.D. degree in 2003 from Dalian University of Technology, China. His research interests are centered around the application of functional materials in light and electrochemistry, including Transdermal Therapeutic (TTS), Systematic Targeting Pharmaceutics (STP), visible sensor guided drug delivery and targeting, fluorescent probes and imaging, detection of virus and tumor, etc.
Dr. Bin Xu
Columbia University, USA
Title: Will update soon
Will update soon
Dr. Subha Bhassu
University Malaya, Malaysia
Title: Genomics and Medicinal chemistry is the future in understanding cellular biology which paves for future in reverse genetics
Prof Dr Subha Bhassu is currently an academician in Institute of Biological Sciences and has 23 years of experience in teaching in various programs and has develop many course structures that are aligned to the Malaysian MQF programmes for University Malaya (2008-2015) and Inti University College (2000 -2004) and also serve as moderator for Biotechnology courses for INTI University College ( 2008-2015) She is also an Head of Section of Aquatic Molecular Biology and Biotechnology of CEBAR( 2014-current) and associate member of IOES and MRC research centers within University Malaya (2014- current). She is also serves as committee member for International Biosafety Committee Member (IBC) of University Malaya and also auditor for Enforcement committee for Biosafety at the Ministry of Environment and Natural Resources (2014-current). In spirit, her research inclination and interest grew since she was in her second year of her degree program when she felt that research is actually very challenging and has kept her going since then. Since 1996, when she joined her Phd Program, her research collaboration, friends, teachers and networks was established from all over the world and her exposure as student led to belief that you need to think out of the box when it comes to research. Of course knowledge and research grants are important for one to do research but the two more important things are even more important than the former which are love and selfless service in research that caters for the students, university, community, industry, country and global needs. Thus in short, she has so far 25 PhD students and 25 masters students whom have graduated and currently having 15 PhD students have supervise to completion 20 undergraduate students and have published more than 60 ISI publications, two book chapters and have three National patents and 9 International patents. She serves currently as a reviewer for PLOS one, GENE, META GENE, Aquaculture, Aquaculture Research and Genomics journal. Her future steps is always have to embark on research with ethics and integrity as her research progress in the aquatic world that involves multidisciplinary approaches and hope to instigate the scientific world on thought provoking ideas that can shift the people’s mind, heart and soul to be more aligned to the world’s needs and happiness.
Prof. Uli Kazmaier
Saarland University, Germany
Title: Flexible total syntheses of biological active natural products
Uli Kazmaier studied chemistry and got his PhD at the University of Stuttgart. Afterwards he joined the research groups of M. T. Reetz (Marburg) and B. M. Trost (Stanford) as a postdoc. In 1992, he moved to Heidelberg starting his own scientific work. In 2000 he received a Novartis Chemistry Lectureship and in 2001 an offer of a full professorship at Saarland University, where he is since that time. He rejected offers from the university of Bayreuth and Heidelberg. His group is not only involved in the development of new synthetic methods but also in their application in natural product syntheses. The major goal is not only the synthesis of a natural product itself, but also the development of concepts to modify these natural products to generate small libraries of potential drugs (natural product medicinal chemistry). He has published more than 280 scientific publications.
Dr. Hong Shen
China Innovation Center of Roche
Title: Discovery of Novel Antiviral Compounds
Dr. Hong Shen received his B.S. from Peking University and Ph.D. from Stanford University. After 9 years working at Merck, Dr. Shen joined the Roche R&D Center in Shanghai in Jan. 2012. He is currently Senior Vice President and Head of China Innovation Center of Roche (CICoR), an integrated drug discovery and early clinical development center of excellence.

Dr. Shen has extensive drug discovery experience in the therapeutic areas of oncology, immunology, antiviral, antibiotics, hypertension, diabetes, thrombosis, atherosclerosis, and obesity. His teams have made major contributions to 11 clinical compounds and 19 preclinical candidates. Dr. Shen also contributed to certain early clinical development programs.

Dr. Shen contributed to more than 110 publications and almost 120 patent applications. He is a Fellow of the Royal Society of Chemistry (FRSC), an extended core member of the R&D-based Pharmaceutical Association Committee (RDPAC) in China, a member of the AACR Chemistry in Cancer Research Working Group (CICR) Steering Committee, and a Steering Advisory Board Member of the Roche Accelerator. Dr. Shen is a recipient of the Zhangjiang Outstanding Innovation and Entrepreneurship Award, the Leo Sternbach Award, and Roche pRED Inventor’s Recognition Gold Medal.
Dr. Petros G Tsoungas
Hellenic Pasteur Institute, Greece
Title: β-Nitroso-o-Naphthoquinone Methide in Synthesis: A still Untamed Intermediate. Challenges Ahead.
Petros G. Tsoungas, born Thessaloniki, Greece. North London Polytechnic, BSc (Hons) Chemistry (1978), UK. University of East Anglia, MSc (1979), PhD (1981) in Organic-Heterocyclic Chemistry, under the supervision of Dr A.J. Boulton UK. Post-Doctoral appointments: Dept of Chemistry, University of Alberta, Alberta, Canada (1984-1985) (NIH fellow), Depts of Chemistry & Chemical Engineering, Organic Chemistry Laboratories, Aristotle University of Thessaloniki, Greece (1986-1988). EKO Refinery (Thessaloniki, Greece, Head of Health and Safety (1989-1992). Research and Policy Appointments: Government/Dept of Research & Technology, Head of Research Centers Network Directorate (1995-2011). Membership or Chairmanship of Boards or Councils of National Research Center "Demokritos", Food Technology Institute, Biomedical Sciences Research Center “Alexander Fleming” and National Education Council of Greece (2005-2011). Senior Researcher (Hellenic Marine Research Centre, Organic Chemistry Section) (2008). Associate Senior Researcher (Hellenic Pasteur Institute (2011-2020 retired). Research interests: Synthesis & Reactivity Profile along with MP2 and DFT endoscopy of N, N-and N,O-heterocycles, β-nitroso-o-quinone methide in synthesis, N,O heterocycles in synthesis and intramolecular H bonding aspects.
Stanford University , USA
Title: Rebalancing Excitatory and Inhibitory Neurotransmission in Neurodegenration
Dr. Montine received his education at Columbia University (BA in Chemistry), the University of Rochester (PhD in Pharmacology), and McGill University (MD, CM). He is Chair of the Department of Pathology at Stanford University and the Stanford Medicine Endowed Professor. Dr. Montine was the 2015 President of the American Association of Neuropathologists and led or co-led NIH initiatives to revise diagnostic guidelines for Alzheimer’s disease, and develop research priorities for the National Alzheimer’s Plan, and for Parkinson’s disease research.

Dr. Montine currently chairs the FDA Advisory Committee on Peripheral and Central Nervous System Drugs. The focus of the Montine Laboratory is on the molecular and biochemical bases of cognitive impairment in aging and neurodegenerative diseases with the goal of defining key pathogenic steps and discovering novel therapeutics.
Dr. Gebhard Thoma
Biomedical Research Novartis Switzerland
Title: Topical JAK inhibitors for atopic dermatitis: From soft to super-soft
Gebhard Thoma is an associate director at Novartis Biomedical Research in Basel. He studied chemistry at the universities of Darmstadt (Germany) and Basel (Switzerland) and received his PhD under the supervision of Prof. Bernd Giese. Following his doctoral studies, he spent a year as a postdoctoral researcher at the University of Pittsburgh in the United States, working with Prof. Dennis P. Curran. In 1993, Gebhard joined the central Research Laboratories of Ciba-Geigy. After the merger of Ciba-Geigy and Sandoz in 1996, which led to the creation of Novartis, he moved to the pharmaceutical research division of the company. In 1999, he was awarded a one-year research sabbatical stay at the Scripps Research Institute in San Diego. Gebhard's specialization lies in medicinal chemistry, and he has been leading projects targeting various drug targets. Some of these include GPCRs, kinases, proteases, and ion channels.